MaxCyte, Inc.
9713 Key West Ave., Suite 400
Rockville
Maryland
20850
United States
Tel: 1-301-944-1700
Fax: 1-301-944-1703
Website: http://www.maxcyte.com/
Email: careers@maxcyte.com
214 articles about MaxCyte, Inc.
-
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
3/12/2024
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) today announced its fourth quarter and full year ended December 31, 2023 financial results and reiterated its 2024 guidance.
-
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
3/4/2024
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today provided revenue guidance for the full year of 2024 and reaffirmed 2023 preliminary results previously announced in January.
-
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
2/9/2024
MaxCyte, Inc. today announced that it will release financial results for the fourth quarter and full year 2023 after the U.S. market close on Tuesday, March 12th, 2024.
-
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers
1/30/2024
MaxCyte, Inc. and Wugen, Inc. announced the signing of a strategic platform license.
-
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
1/23/2024
MaxCyte, Inc. and Imugene announced the signing of a strategic platform license.
-
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
1/8/2024
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) today provided a preliminary update on financial results for the fourth quarter and full year ended December 31, 2023.
-
MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline
1/3/2024
MaxCyte, Inc. today announced the signing of a strategic platform license (SPL).
-
MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director
1/2/2024
MaxCyte, Inc. is pleased to confirm the appointment of Maher Masoud as President and Chief Executive Officer of MaxCyte effective as of January 1, 2024.
-
MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023
12/11/2023
MaxCyte, Inc. announced that Maher Masoud has been named President and Chief Executive Officer of MaxCyte, succeeding Doug Doerfler, who will retire as President and Chief Executive Officer, effective January 1, 2024.
-
MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member
11/16/2023
MaxCyte, Inc. announced that it has joined the Alliance for mRNA Medicines, as a founding member.
-
MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance
11/8/2023
MaxCyte, Inc. announced financial results for the third quarter ended September 30, 2023.
-
MaxCyte to Participate in Two Upcoming November 2023 Investor Conferences
11/6/2023
MaxCyte, Inc. announced Company management will participate at two upcoming investor conferences.
-
MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance
10/4/2023
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) today announced preliminary revenue for the third quarter ended September 30, 2023 and updated its full year 2023 revenue guidance.
-
MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing
9/6/2023
MaxCyte, Inc. today announced the appointment of Ali Soleymannezhad as Executive Vice President of Bioprocessing, effective August 21, 2023.
-
MaxCyte to Participate in Baird Global Healthcare Conference
9/5/2023
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced Company management will participate at the Baird Global Healthcare Conference on Wednesday, September 13th at 2:35 p.m. Eastern Time.
-
MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance
8/9/2023
MaxCyte, Inc. announced financial results for the second quarter and six months ended June 30, 2023.
-
MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients
8/1/2023
MaxCyte, Inc. announced the signing of a strategic partnership with Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies.
-
MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023
7/13/2023
MaxCyte, Inc. today announced that it will release financial results for the second quarter 2023 after the U.S. market close on Wednesday, August 9th, 2023.
-
MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies
7/10/2023
MaxCyte, Inc. today announced the signing of a strategic platform license (SPL) of MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to Vittoria Biotherapeutics.
-
MaxCyte Signs Strategic Platform License with Lyell Immunopharma
7/6/2023
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT) today announced the signing of a strategic platform license (SPL) with Lyell Immunopharma, Inc., a clinical stage T cell reprogramming company.